Aclaris Therapeutics启动二期B阶段计划,涵盖哮喘与特应性皮炎,预计2026年下半年展开

美股速递
Feb 24

Aclaris Therapeutics宣布,其针对哮喘及特应性皮炎的二期B阶段临床研究计划预计将于2026年下半年正式启动。这一进展标志着公司在炎症性皮肤病与呼吸疾病治疗领域的研发迈出关键一步。

该计划旨在评估候选药物在更广泛患者群体中的疗效与安全性,为后续临床试验奠定基础。随着研究推进,公司有望进一步明确其创新疗法的市场潜力与发展路径。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10